Matterworks
Seed
Matterworks: AI-powered metabolomics for accelerated therapeutic research and development.
Founded
2019Matterworks: AI-powered metabolomics for accelerated therapeutic research and development.
Matterworks, founded with the mission to revolutionize metabolomics, leverages AI and analytical chemistry to accelerate therapeutic research, development, and manufacturing. Their core vision is to make biological data more accessible and actionable, thereby enhancing the efficiency of biotechnological advancements. Matterworks offers an AI-enabled platform that deciphers complex biochemical data, providing tools for understanding and predicting biological processes. Their market focus includes pharmaceutical companies, research institutions, and biotech firms seeking to streamline their R&D efforts.
Notable affiliated individuals include experts in AI, biochemistry, and data science, although specific names are not provided. Investors likely include venture capital firms specializing in biotech and AI technologies. Key achievements encompass the successful deployment of their AI platform in various therapeutic research projects, demonstrating significant improvements in data analysis speed and accuracy. Overall, Matterworks has made a substantial impact by enabling more efficient and insightful metabolomics research, thereby accelerating the development of new therapies.
Companies similar to Matterworks include Manifold Bio, Metaphore Biotechnologies, ReviveMed and Metanovas Biotech.
Matterworks was founded in 2019.
Matterworks' headquarters is located in Somerville, MA, US.
Matterworks' most recent funding round was for $7.5M (USD) in August 2023.
As of Aug 14, 2023, Matterworks has raised a total of $13.8M (USD).
Matterworks has 24 employees as of Feb 4, 2024.
ReviveMed
